A detailed history of Anderson Hoagland & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Anderson Hoagland & CO holds 2,434 shares of ABBV stock, worth $445,616. This represents 0.05% of its overall portfolio holdings.

Number of Shares
2,434
Previous 2,651 8.19%
Holding current value
$445,616
Previous $454,000 5.73%
% of portfolio
0.05%
Previous 0.05%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$163.84 - $199.33 $35,553 - $43,254
-217 Reduced 8.19%
2,434 $480,000
Q1 2024

Apr 11, 2024

BUY
$159.82 - $182.1 $34,680 - $39,515
217 Added 8.92%
2,651 $482,000
Q3 2023

Oct 10, 2023

BUY
$133.59 - $154.65 $325,158 - $376,418
2,434 New
2,434 $362,000
Q3 2018

Oct 18, 2018

SELL
$88.91 - $98.84 $1.06 Million - $1.17 Million
-11,875 Closed
0 $0
Q1 2018

Apr 24, 2018

BUY
$92.01 - $123.21 $438,887 - $587,711
4,770 Added 67.14%
11,875 $1.12 Million
Q4 2017

Jan 18, 2018

BUY
$89.56 - $98.21 $636,323 - $697,782
7,105
7,105 $687,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Anderson Hoagland & CO Portfolio

Follow Anderson Hoagland & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anderson Hoagland & CO, based on Form 13F filings with the SEC.

News

Stay updated on Anderson Hoagland & CO with notifications on news.